Cancer Genetics Inc announces NYS licensure for FHACT®, which will allow the company to market the test in New York State
CGI’s full range of oncology focused testing services will be available to an additional 19 million individuals in the US RUTHERFORD, NJ (April 01, 2015): Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, today announced that it has executed an agreement with America’s Choice Provider Network® (ACPN®), an independent national […]
Collaborations with Keck School of Medicine of USC, University of Alabama School of Medicine, and Westchester Medical Center at New York Medical College provide insight into the diagnosis and management of challenging cancers. The collaborations leverage the power of CGI’s unique, proprietary genomic panels, including MatBA® for diffuse large B-cell lymphoma (DLBCL), which is the […]
Fourth Quarter Revenues up 118 Percent Year over Year to $4 million Full-Year 2014 Revenue Increase up 54 Percent over 2013 to $10.2 Million Cancer Genetics to Host Conference Call Today, Thursday March 12th at 8:30 am Eastern Time / 5:30 am Pacific Time RUTHERFORD, N.J., March 12, 2015 – Cancer Genetics, Inc. (Nasdaq: CGIX), […]
Cancer Genetics to Report Fourth Quarter and Fiscal Year 2014 Financial Results on Thursday, March 12
> CGI’s genomic signature, developed in a research collaboration with Memorial Sloan-Kettering, predicts metastasis for clear-cell renal cell carcinoma (ccRCC) > Clear cell renal cell carcinoma is the most common form of kidney cancer with nearly 43,000 new cases in the US each year and 200,000 globally per year RUTHERFORD, NJ, February 24, 2015 (Globe […]
CGI’s unique next generation sequencing (NGS) panel, Focus::CLLTM, will be used to assess genetic aberrations and mutations that are clinically relevant and validated for CLL, the most common form of leukemia in the Western hemisphere. CLL accounts for one-third of all leukemias and the Focus::CLLTM panel helps in determining patient outcome and treatment selection. RUTHERFORD, […]
CEO and President Panna Sharma to participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference from February 18th to 20th, 2015 in Snowbird, Utah.
Cancer Genetics, Inc. announces appointment of Randy Goodman, Ph.D. as Director of Reimbursement and Clinical Revenue Cycle Management.
Cancer Genetics, Inc. announces that it has begun testing for two clinical trials focused on diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). The total value of the contracts is expected to exceed $2.5 million USD.
Cancer Genetics announces the launch of their ExpandDx™ collaborative testing program. The technical-only testing service provides community hospitals and pathology labs with the most advanced testing technologies available, and facilitates increased collaboration on both atypical and difficult cancer cases.
Cancer Genetics, Inc. announced today that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License will allow the company to provide its state-of-the art oncology testing services for patient samples from the state of California.
Cancer Genetics, Inc. announces the addition of Venkatadri Bobba to Cancer Genetics India’s Board of Directors.
Cancer Genetics, Inc. announced today that Rob Fannon has joined the company as vice president of operations in the Raleigh/Research Triangle Park (RTP), North Carolina location. Fannon, previously with Roche Molecular’s BioSpecimen Management division, brings more than 10 years of operations, client management, molecular test and panel development, and biorepository management experience to CGI.
Cancer Genetics, Inc. announced today that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.
Cancer Genetics, Inc., announces launch of next-generation sequencing (NGS) based panel for chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Focus::CLL™ is the only NGS panel to assess seven biomarkers with clinical utility for prognosis and treatment selection of CLL/SLL.
Cancer Genetics, Inc.announced today the addition of Howard McLeod, Pharm. D., and Geoffrey Harris to the Company’s Board of Directors.
Cancer Genetics, Inc. announced today that it will present at the 26th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 2, 2014. Representatives from the company will speak at 8:10 am EST.
Cancer Genetics, Inc. announced today that it will present two posters on diffuse large B-cell lymphoma (DLBCL) at the 56th annual meeting of the American Society of Hematology (ASH), in San Francisco, CA. A third poster on multiple myeloma (MM) will be presented by OncoSpire Genomics, CGI’s joint venture with Mayo Clinic.
Cancer Genetics, Inc. announced it ranked 303 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. CGI grew 296% percent as measured by revenues during this period.